US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist
  • 5.540
  • +0.370+7.16%
Close Nov 27 16:00 ET
  • 5.790
  • +0.250+4.51%
Post 20:01 ET
178.36MMarket Cap-4755P/E (TTM)

About Sagimet Biosciences Company

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Company Profile

SymbolSGMT
Company NameSagimet Biosciences
Listing DateJul 14, 2023
Issue Price16.00
Founded2006
CEOMr. David Happel
MarketNASDAQ
Employees10
Fiscal Year Ends12-31
Address155 Bovet Road,Suite 303
CitySan Mateo
ProvinceCalifornia
CountryUnited States of America
Zip Code94402
Phone1-650-561-8600
Websitehttp://www.sagimet.com

Company Executives

  • Name
  • Position
  • Salary
  • David Happel
  • President, Chief Executive Officer and Director
  • 2.69M
  • Dr. Eduardo Bruno Martins, D.Phil.,M.D.
  • Chief Medical Officer
  • 1.51M
  • Thierry Chauche
  • Chief Financial Officer and Principal Accounting Officer
  • --
  • Elizabeth Rozek
  • General Counsel and Chief Compliance Officer
  • --
  • George Kemble, PhD
  • Executive Chairman of the Board
  • 930.22K
  • Jennifer Ann Jarrett
  • Independent Director
  • --
  • Elizabeth Grammer
  • Independent Director
  • 43.00K
  • Dr. Anne M. Phillips, M.D.
  • Independent Director
  • --
  • Dr. Merdad V. Parsey, M.D.,PhD
  • Independent Director
  • 41.50K
  • Dr. Beth C. Seidenberg,M.D.
  • Independent Director
  • 14.38K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data